Pharmacological Properties of Salmeterol
- Registration Number
- NCT02558088
- Lead Sponsor
- University of Copenhagen
- Brief Summary
The objective of the study is to help establish a urinary threshold for salmeterol on the World Anti-doping Agency prohibited list, to avoid supratherapeutic of this substance in competitive sports.
Hence, there is no hypothesis as such.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 11
Inclusion Criteria
- Male
- 18-45 years
- Healthy
Exclusion Criteria
- Chronic disease
- Smoking
- Habitual use of medicine
- Allergy towards salmeterol
- Unable to exercise on a bike ergometer
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description salmeterol Salmeterol -
- Primary Outcome Measures
Name Time Method Urine concentration of salmeterol 0-24 hours after administration of the study drug
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of salmeterol's beta-2 adrenergic agonist activity in healthy trained males?
How does salmeterol's pharmacokinetics compare to other long-acting beta-2 agonists in athletic populations?
Which urinary biomarkers correlate with supratherapeutic salmeterol levels in anti-doping contexts?
What adverse events are associated with supratherapeutic salmeterol exposure in athletes and how are they managed?
How do CYP3A4 and CYP2C19 polymorphisms influence salmeterol metabolism in healthy male athletes?
Trial Locations
- Locations (1)
Bispebjerg Hospital
🇩🇰Copenhagen, Select State, Denmark